Semaglutide is a GLP -1 receptor agonist, that means it acts like a glucagon like peptide. This drug was first designed as a treatment for diabetic patients, however it was found to have profound weight loss properties in patients. This was a huge benefit to diabetic patients, but also the population as a whole. The GLP-1 was shown to affect appetite and food intake. It decrease a person’s appetite which in turn leads to weight loss.
Semaglutides are a weekly injection that patients can do in the comfort of their own home after the first 4 weeks of in office treatments.